Fig. 2.

ADCC of mu-adecatumumab and adecatumumab with human and murine effector cells. a Kato III cells and non-stimulated human PBMC were co-incubated at a ratio of 1:20 in the presence of indicated adecatumumab (filled squares) and mu-adecatumumab (filled triangles) concentrations. Human IgG1 (open squares) and mouse IgG2a (open triangles) isotype control antibodies served as negative controls. ADCC activity was measured after 4 h. Target cell lysis was determined by PI uptake using flow cytometry. b Kato III cells and IL-2 pre-stimulated murine NK cells were co-incubated at a ratio of 1:50 in the presence of indicated adecatumumab (filled squares) and mu-adecatumumab (filled triangles) concentrations. Human IgG1 (open squares) and mouse IgG2a (open triangles) isotype control antibodies were used as negative controls. ADCC activity was measured after 10 h. Error bars show standard deviations of triplicate wells